L
Argenx announced positive results for its drug Vyvgart, recently in phase three of clinical trials for treating myositis, showing significant improvements in patients, which resulted in an increase in its stock price. (translated)
Argenx annonce des résultats positifs pour son médicament Vyvgart contre la myosite (2)
